

16102660D

HOUSE BILL NO. 498

Offered January 13, 2016

Prefiled January 8, 2016

A *BILL to amend and reenact § 54.1-3303 of the Code of Virginia, relating to TPA-certified optometrists; prescription of certain Schedule II controlled substances.*

Patron—Hodges

Referred to Committee on Health, Welfare and Institutions

Be it enacted by the General Assembly of Virginia:**1. That § 54.1-3303 of the Code of Virginia is amended and reenacted as follows:****§ 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic purposes only.**

A. A prescription for a controlled substance may be issued only by a practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled substances, or by a licensed nurse practitioner pursuant to § 54.1-2957.01, a licensed physician assistant pursuant to § 54.1-2952.1, or a TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32. The prescription shall be issued for a medicinal or therapeutic purpose and may be issued only to persons or animals with whom the practitioner has a bona fide practitioner-patient relationship.

For purposes of this section, a bona fide practitioner-patient-pharmacist relationship is one in which a practitioner prescribes, and a pharmacist dispenses, controlled substances in good faith to his patient for a medicinal or therapeutic purpose within the course of his professional practice. In addition, a bona fide practitioner-patient relationship means that the practitioner shall (i) ensure that a medical or drug history is obtained; (ii) provide information to the patient about the benefits and risks of the drug being prescribed; (iii) perform or have performed an appropriate examination of the patient, either physically or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically; except for medical emergencies, the examination of the patient shall have been performed by the practitioner himself, within the group in which he practices, or by a consulting practitioner prior to issuing a prescription; and (iv) initiate additional interventions and follow-up care, if necessary, especially if a prescribed drug may have serious side effects.

For the purpose of prescribing a Schedule VI controlled substance to a patient via telemedicine services as defined in § 38.2-3418.16, a prescriber may establish a bona fide practitioner-patient relationship by an examination through face-to-face interactive, two-way, real-time communications services or store-and-forward technologies when all of the following conditions are met: (a) the patient has provided a medical history that is available for review by the prescriber; (b) the prescriber obtains an updated medical history at the time of prescribing; (c) the prescriber makes a diagnosis at the time of prescribing; (d) the prescriber conforms to the standard of care expected of in-person care as appropriate to the patient's age and presenting condition, including when the standard of care requires the use of diagnostic testing and performance of a physical examination, which may be carried out through the use of peripheral devices appropriate to the patient's condition; (e) the prescriber is actively licensed in the Commonwealth and authorized to prescribe; (f) if the patient is a member or enrollee of a health plan or carrier, the prescriber has been credentialed by the health plan or carrier as a participating provider and the diagnosing and prescribing meets the qualifications for reimbursement by the health plan or carrier pursuant to § 38.2-3418.16; and (g) upon request, the prescriber provides patient records in a timely manner in accordance with the provisions of § 32.1-127.1:03 and all other state and federal laws and regulations. Nothing in this paragraph shall permit a prescriber to establish a bona fide practitioner-patient relationship for the purpose of prescribing a Schedule VI controlled substance when the standard of care dictates that an in-person physical examination is necessary for diagnosis. Nothing in this paragraph shall apply to: (1) a prescriber providing on-call coverage per an agreement with another prescriber or his prescriber's professional entity or employer; (2) a prescriber consulting with another prescriber regarding a patient's care; or (3) orders of prescribers for hospital out-patients or in-patients.

Any practitioner who prescribes any controlled substance with the knowledge that the controlled substance will be used otherwise than medicinally or for therapeutic purposes shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the distribution or possession of controlled substances.

B. In order to determine whether a prescription that appears questionable to the pharmacist results from a bona fide practitioner-patient relationship, the pharmacist shall contact the prescribing practitioner

INTRODUCED

HB498

59 or his agent and verify the identity of the patient and name and quantity of the drug prescribed. The
60 person knowingly filling an invalid prescription shall be subject to the criminal penalties provided in
61 § 18.2-248 for violations of the provisions of law relating to the sale, distribution or possession of
62 controlled substances.

63 No prescription shall be filled unless there is a bona fide practitioner-patient-pharmacist relationship.
64 A prescription not issued in the usual course of treatment or for authorized research is not a valid
65 prescription.

66 C. Notwithstanding any provision of law to the contrary and consistent with recommendations of the
67 Centers for Disease Control and Prevention or the Department of Health, a practitioner may prescribe
68 Schedule VI antibiotics and antiviral agents to other persons in close contact with a diagnosed patient
69 when (i) the practitioner meets all requirements of a bona fide practitioner-patient relationship, as
70 defined in subsection A, with the diagnosed patient; (ii) in the practitioner's professional judgment, the
71 practitioner deems there is urgency to begin treatment to prevent the transmission of a communicable
72 disease; (iii) the practitioner has met all requirements of a bona fide practitioner-patient relationship, as
73 defined in subsection A, for the close contact except for the physical examination required in clause (iii)
74 of subsection A; and (iv) when such emergency treatment is necessary to prevent imminent risk of
75 death, life-threatening illness, or serious disability.

76 D. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-state
77 practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine authorized to issue such
78 prescription if the prescription complies with the requirements of this chapter and the Drug Control Act
79 (§ 54.1-3400 et seq.).

80 E. A licensed nurse practitioner who is authorized to prescribe controlled substances pursuant to
81 § 54.1-2957.01 may issue prescriptions or provide manufacturers' professional samples for controlled
82 substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
83 patient for a medicinal or therapeutic purpose within the scope of his professional practice.

84 F. A licensed physician assistant who is authorized to prescribe controlled substances pursuant to
85 § 54.1-2952.1 may issue prescriptions or provide manufacturers' professional samples for controlled
86 substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
87 patient for a medicinal or therapeutic purpose within the scope of his professional practice.

88 G. A TPA-certified optometrist who is authorized to prescribe controlled substances pursuant to
89 Article 5 (§ 54.1-3222 et seq.) of Chapter 32 may issue prescriptions in good faith or provide
90 manufacturers' professional samples to his patients for medicinal or therapeutic purposes within the
91 scope of his professional practice for the drugs specified on the TPA-Formulary, established pursuant to
92 § 54.1-3223, which shall be limited to (i) *Schedule II controlled substances as defined in § 54.1-3448 of*
93 *the Drug Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in combination with*
94 *acetaminophen*; (ii) oral analgesics included in Schedules III through VI, as defined in §§ 54.1-3450 and
95 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.), which are appropriate to relieve ocular pain;
96 ~~(ii);~~ (iii) other oral Schedule VI controlled substances, as defined in § 54.1-3455 of the Drug Control
97 Act, appropriate to treat diseases and abnormal conditions of the human eye and its adnexa; ~~(iii);~~ (iv)
98 topically applied Schedule VI drugs, as defined in § 54.1-3455 of the Drug Control Act; and ~~(iv);~~ (v)
99 intramuscular administration of epinephrine for treatment of emergency cases of anaphylactic shock.

100 H. The requirement for a bona fide practitioner-patient relationship shall be deemed to be satisfied by
101 a member or committee of a hospital's medical staff when approving a standing order or protocol for the
102 administration of influenza vaccinations and pneumococcal vaccinations in a hospital in compliance with
103 § 32.1-126.4.